Y-mAbs Therapeutics Inc.

10/09/2019 | Press release | Archived content

SIOP 2019 Preliminary Tolerability Assesment of Naxitamab Therapy Phase 2 Osteosarcoma Trial (c0e61c)

Y-mAbs Therapeutics Inc. published this content on October 09, 2019, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 11, 2025 at 18:51 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io